Opportunity Information: Apply for CDC RFA GH13 1301
Apply for CDC RFA GH13 1301
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Cooperative Agreement on Immunization with the World Health Organization (WHO)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.185 Immunization Research, Demonstration, Public Information and EducationTraining and Clinical Skills Improvement Projects.
- This funding opportunity was created on Feb 1, 2013 and posted on Jun 29, 2012.
- Applicants must submit their applications by Sep 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $300,000,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- The eligible applicant for this funding opportunity is the World Health Organization (WHO). No other applications are solicited.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Cooperative Agreement on Immunization with the World Health Organization (WHO) is a CDC funding opportunity designed to support major global vaccination and disease control efforts backed by the US Government, specifically the Global Polio Eradication Initiative, the Global Measles Initiative, and the Global Immunization Vision and Strategy for 2006 to 2015. The core idea is to provide substantial resources directly to WHO so it can carry out and coordinate high-impact immunization work in developing countries, with an emphasis on stopping, eliminating, or sharply reducing vaccine-preventable diseases (VPDs). The agreement is built around the practical needs of large-scale global immunization programs: finding cases quickly, confirming them accurately through laboratories, organizing vaccination activities that can reach missed populations, and strengthening routine immunization systems so progress is sustained rather than temporary.
A central focus of the program is surveillance for polio, measles, and other vaccine-preventable diseases. Surveillance in this context means supporting the systems that detect and investigate suspected cases, collect and ship specimens, analyze data, and use that information to guide rapid public health action. Alongside surveillance, the opportunity highlights support for global laboratory networks, particularly those tied to polio and measles. These lab networks are critical because eradication and elimination goals depend on the ability to confirm cases, distinguish wild-type viruses from vaccine-derived strains where relevant, monitor transmission patterns, and provide standardized, comparable results across countries. In practice, funding under this type of cooperative agreement helps maintain lab capacity, quality assurance, training, specimen transport logistics, and the coordination mechanisms that allow many national labs to operate as a unified network.
The award also supports planning and implementation of supplemental immunization campaigns, which are the large, time-bound vaccination pushes often used to close immunity gaps, stop outbreaks, and accelerate progress toward elimination targets. Campaign support can include operational planning, microplanning to identify and reach high-risk or under-immunized groups, social mobilization and communications, training of vaccinators and supervisors, monitoring of campaign quality, and post-campaign assessments. Importantly, the opportunity pairs these campaign activities with efforts to strengthen routine immunization delivery systems and capacities. Routine immunization strengthening typically includes improving immunization service delivery, cold chain and logistics, data quality and use, workforce capacity, supportive supervision, and integration with other primary health services. This matters because eradication and elimination efforts can stall if routine coverage remains weak and new cohorts of unvaccinated children continue to accumulate.
While polio and measles are emphasized, the description makes clear that the agreement can also be used for other global health priorities that align with CDC goals. That gives CDC and WHO room to address additional needs connected to immunization and disease prevention when they are consistent with broader public health objectives, especially when those activities reinforce surveillance capacity, laboratory readiness, outbreak response, and immunization system performance.
From an administrative standpoint, the opportunity is a discretionary grant using a cooperative agreement mechanism, meaning CDC expects to have substantial involvement in the funded activities compared with a standard grant. The funding activity category is health, and the CFDA listing includes 93.185 (Immunization Research, Demonstration, Public Information and Education; Training and Clinical Skills Improvement Projects). The opportunity anticipated a single award, with an estimated total funding level of 300,000,000. There is no cost-sharing or matching requirement noted. The posting date was June 29, 2012, with an original and current closing date of September 7, 2012, and an archive date of October 7, 2012, indicating this specific notice is historical rather than currently open.
Eligibility is strictly limited: the only eligible applicant is the World Health Organization, and no other applications are solicited. In other words, this is a targeted funding action intended to resource WHO as the implementing and coordinating partner for global immunization objectives rather than a competitive opportunity open to states, universities, NGOs, or other entities.
For access or technical difficulties related to the full announcement, the contact listed is the CDC Procurement and Grants Office (PGO), Technical Information Management Section (TIMS), reachable by phone at 770-488-2700. The notice also mentions that the additional information link is not active and directs readers to use the "Full Announcement" section of the posting for complete details.
FAQs: Cooperative Agreement on Immunization with the World Health Organization (WHO) (CDC)
What is this funding opportunity?
This is a CDC discretionary funding opportunity using a cooperative agreement mechanism to support major global vaccination and disease control efforts implemented and coordinated by the World Health Organization (WHO), with an emphasis on reducing, eliminating, or stopping vaccine-preventable diseases in developing countries.
What is the main purpose of the cooperative agreement?
The purpose is to provide substantial resources directly to WHO so it can carry out and coordinate high-impact immunization work at scale. The described work centers on strong disease surveillance, reliable laboratory confirmation, supplemental immunization campaigns to close immunity gaps, and strengthening routine immunization systems so gains are sustained.
Which global initiatives are specifically referenced?
The opportunity specifically references support aligned with: the Global Polio Eradication Initiative, the Global Measles Initiative, and the Global Immunization Vision and Strategy (2006 to 2015).
Which diseases are emphasized?
Polio and measles are central focus areas, along with other vaccine-preventable diseases (VPDs) as relevant to surveillance and control objectives.
What types of activities are supported under the surveillance focus?
Supported surveillance activities include systems to detect and investigate suspected cases, collect and ship specimens, analyze and use data, and guide rapid public health action based on surveillance findings.
How do laboratory networks fit into this opportunity?
The opportunity highlights support for global laboratory networks, particularly those tied to polio and measles. These networks are important for confirming cases, distinguishing viruses (including differentiating wild-type from vaccine-derived strains where relevant), monitoring transmission patterns, and producing standardized, comparable results across countries.
What kinds of laboratory support are described?
Examples of support described include maintaining laboratory capacity, quality assurance, training, specimen transport logistics, and coordination mechanisms that allow many national laboratories to function as a unified network.
What are supplemental immunization campaigns in this context?
Supplemental immunization campaigns are large, time-bound vaccination efforts intended to close immunity gaps, stop outbreaks, and accelerate progress toward elimination targets.
What campaign-related activities can be supported?
The opportunity describes campaign support such as operational planning, microplanning to identify and reach high-risk or under-immunized groups, social mobilization and communications, training of vaccinators and supervisors, monitoring of campaign quality, and post-campaign assessments.
Does the opportunity also support routine immunization system strengthening?
Yes. In addition to campaigns, the opportunity pairs activities with strengthening routine immunization delivery systems and capacities to ensure progress is durable rather than temporary.
What kinds of routine immunization strengthening activities are mentioned?
Routine immunization strengthening is described as including improvements in immunization service delivery, cold chain and logistics, data quality and use, workforce capacity, supportive supervision, and integration with other primary health services.
Can the agreement be used for priorities beyond polio and measles?
Yes. While polio and measles are emphasized, the description states the agreement can also be used for other global health priorities that align with CDC goals, especially when they reinforce surveillance capacity, laboratory readiness, outbreak response, and immunization system performance.
What is the funding mechanism and what does it imply?
The mechanism is a cooperative agreement. This implies CDC expects substantial involvement in the funded activities compared with a standard grant.
What is the funding activity category?
The funding activity category is Health.
What CFDA number is associated with this opportunity?
The CFDA listing includes 93.185 (Immunization Research, Demonstration, Public Information and Education; Training and Clinical Skills Improvement Projects).
How many awards were anticipated?
The notice anticipated a single award.
What was the estimated total funding level?
The estimated total funding level was 300,000,000.
Is cost sharing or matching required?
No cost-sharing or matching requirement is noted in the provided information.
Who is eligible to apply?
Eligibility is strictly limited to the World Health Organization (WHO). No other applications are solicited.
Is this a competitive opportunity open to states, universities, NGOs, or other entities?
No. This is described as a targeted funding action intended to resource WHO as the implementing and coordinating partner, rather than a competitive opportunity open to other organizations.
What were the key dates for this opportunity?
The posting date was June 29, 2012. The original and current closing date was September 7, 2012. The archive date was October 7, 2012.
Is this opportunity currently open?
No. The dates and archive status indicate this specific notice is historical rather than currently open.
What should someone do if they have trouble accessing the full announcement?
For access or technical difficulties related to the full announcement, the contact listed is the CDC Procurement and Grants Office (PGO), Technical Information Management Section (TIMS) at 770-488-2700.
The notice mentions an additional information link is not active. Where should details be found?
The notice directs readers to use the "Full Announcement" section of the posting for complete details, since the additional information link is not active.
Browse more opportunities from the same category: Health
Next opportunity: FY 2012 Cooperating Technical Partners (CTP) Program Region II
Previous opportunity: Condition Assessment and Treatment Evaluation of the Support Boulder beneath Holly Tower
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH13 1301
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH13 1301) also looked into and applied for these:
| Funding Opportunity |
|---|
| National Indian Health Outreach Apply for HHS 2012 IHS NIHOE 0002 Funding Number: HHS 2012 IHS NIHOE 0002 Agency: Indian Health Service Category: Health Funding Amount: $150,000 |
| PPHF 2012 National Public Health Improvement Initative (NPHII) Capacity Building Assistance to Strengthen Public Health Infrastructure and Performance financed solely by 2012 Prevention and Public Health Funds Apply for CDC RFA CD10 101103PPHF12 Funding Number: CDC RFA CD10 101103PPHF12 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| PPHF 2012 Health Care Surveillance/Health Statistics Surveillance Program Announcement Behavioral Risk Factor Surveillance System Financed in part by 2012 Prevention and Public Health Funds Apply for CDC RFA SO11 11010201PPHF12 Funding Number: CDC RFA SO11 11010201PPHF12 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| PPHF 2012 Health Care Surveillance/Health Statistics Surveillance Program Announcement Behavioral Risk Factor Surveillance System (Pacific Jurisdictions) Financed in Part by 2012 Prevention and Public Health Funds Apply for CDC RFA SO11 11020201PPHF12 Funding Number: CDC RFA SO11 11020201PPHF12 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| Tuberculosis Regional Training and Medical Consultation Centers Apply for CDC RFA PS13 1304 Funding Number: CDC RFA PS13 1304 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,398,944 |
| Limited Competition National NeuroAIDS Tissue Consortium (NNTC) Clinical Sites (U24) Apply for RFA MH 13 070 Funding Number: RFA MH 13 070 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National NeuroAIDS Tissue Consortium (NNTC) Data Coordinating Center (DCC) (U24) Apply for RFA MH 13 071 Funding Number: RFA MH 13 071 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| NIAMS Clinical Trial Outcomes Instrument Development Grant Program (U01) Apply for RFA AR 13 004 Funding Number: RFA AR 13 004 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| NIMHD Transdisciplinary Collaborative Centers for Health Disparities Research (U54) Apply for RFA MD 12 007 Funding Number: RFA MD 12 007 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Institutional Clinical and Translational Science Award (U54) Apply for RFA TR 12 006 Funding Number: RFA TR 12 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Affordable Care Act Maternal, Infant and Early Childhood Home Visiting Program Apply for HRSA 12 156 Funding Number: HRSA 12 156 Agency: Health Resources and Services Administration Category: Health Funding Amount: $3,000,000 |
| Identification and Analysis of Causal Variants Follow Up on Genome Wide Association Studies for Arthritis and Musculoskeletal and Skin Diseases (R21) Apply for PAR 12 230 Funding Number: PAR 12 230 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Identification and Analysis of Causal Variants Follow Up on Genome Wide Association Studies for Arthritis and Musculoskeletal and Skin Diseases (R01) Apply for PAR 12 236 Funding Number: PAR 12 236 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R21) Apply for PA 12 234 Funding Number: PA 12 234 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R01) Apply for PA 12 235 Funding Number: PA 12 235 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Specialized Neuroscience Research Program (SNRP) (U54) Apply for RFA NS 13 004 Funding Number: RFA NS 13 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stem Cells and Alcohol induced Tissue Injuries (R01) Apply for PA 12 233 Funding Number: PA 12 233 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stem Cells and Alcohol induced Tissue Injuries (R21) Apply for PA 12 232 Funding Number: PA 12 232 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (P50) Apply for RFA DA 13 003 Funding Number: RFA DA 13 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition Renewal of Centers of Biomedical Research Excellence (COBRE)P20 Apply for PAR 12 224 Funding Number: PAR 12 224 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH13 1301", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.